Stock 300485 BEIJING SCIENCE SUN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Beijing Science Sun Pharmaceutical Co., Ltd.

Equities

300485

CNE100002110

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 09/05/2024 BST 		5-day change 1st Jan Change
8.08 CNY -3.23% Intraday chart for Beijing Science Sun Pharmaceutical Co., Ltd. +5.62% -23.70%
04-26 Beijing Science Sun Pharmaceutical Co., Ltd. agreed to acquire 5.6664% stake in Suzhou Inhal Pharma Co., Ltd. from Ningbo Menovo Ruihe Equity Investment Partnership for CNY 10 million. CI
04-25 Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 4,750 4,362 7,109 6,353 5,770 5,101
Enterprise Value (EV) 1 3,392 3,084 5,929 5,057 4,649 3,927
P/E ratio 16.6 x 29.1 x 46.1 x 15.7 x 27.9 x 50.4 x
Yield 1.22% 0.69% 0.44% 1.27% 0.72% 0.21%
Capitalization / Revenue 3.33 x 3.66 x 6.5 x 6.05 x 7.86 x 10.7 x
EV / Revenue 2.38 x 2.59 x 5.42 x 4.81 x 6.33 x 8.24 x
EV / EBITDA 11 x 19.5 x 37 x 33.5 x 65.5 x 457 x
EV / FCF -29.1 x -175 x 60.3 x 54.7 x 104 x -118 x
FCF Yield -3.43% -0.57% 1.66% 1.83% 0.96% -0.84%
Price to Book 1.86 x 1.63 x 2.54 x 1.96 x 1.71 x 1.48 x
Nbr of stocks (in thousands) 484,166 484,166 481,666 481,666 481,666 481,666
Reference price 2 9.810 9.010 14.76 13.19 11.98 10.59
Announcement Date 27/03/19 15/04/20 29/03/21 30/03/22 29/03/23 09/04/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1,428 1,191 1,094 1,051 734.5 476.6
EBITDA 1 307.5 158.2 160.4 150.9 70.95 8.601
EBIT 1 284.8 132.5 123.6 95.41 24.24 -39.75
Operating Margin 19.95% 11.13% 11.29% 9.08% 3.3% -8.34%
Earnings before Tax (EBT) 1 330.6 172.7 179.3 439 254.6 122.2
Net income 1 283.1 148.6 154.9 402.3 204.7 102.9
Net margin 19.83% 12.48% 14.16% 38.28% 27.87% 21.6%
EPS 2 0.5900 0.3100 0.3200 0.8400 0.4300 0.2100
Free Cash Flow 1 -116.4 -17.67 98.25 92.42 44.63 -33.15
FCF margin -8.15% -1.48% 8.98% 8.8% 6.08% -6.96%
FCF Conversion (EBITDA) - - 61.25% 61.23% 62.91% -
FCF Conversion (Net income) - - 63.42% 22.97% 21.8% -
Dividend per Share 2 0.1200 0.0620 0.0650 0.1680 0.0860 0.0220
Announcement Date 27/03/19 15/04/20 29/03/21 30/03/22 29/03/23 09/04/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 1,358 1,278 1,180 1,296 1,122 1,174
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -116 -17.7 98.2 92.4 44.6 -33.1
ROE (net income / shareholders' equity) 11.6% 5.6% 5.44% 12.9% 6.05% 2.8%
ROA (Net income/ Total Assets) 6.83% 2.98% 2.67% 1.87% 0.43% -0.69%
Assets 1 4,146 4,995 5,813 21,564 47,098 -14,896
Book Value Per Share 2 5.280 5.520 5.820 6.740 7.000 7.130
Cash Flow per Share 2 1.180 1.630 1.400 0.3400 0.4700 0.2500
Capex 1 198 111 118 45.9 43.3 52.9
Capex / Sales 13.87% 9.36% 10.77% 4.37% 5.89% 11.1%
Announcement Date 27/03/19 15/04/20 29/03/21 30/03/22 29/03/23 09/04/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
BEIJING SCIENCE SUN PHARMACEUTICAL CO., LTD. Stock Beijing Science Sun Pharmaceutical Co., Ltd.
-23.70% 539M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+30.38% 684B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.51% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.36% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.30% 329B
ABBVIE INC. Stock AbbVie Inc.
+3.73% 284B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.70% 240B
NOVARTIS AG Stock Novartis AG
+8.78% 208B
ROCHE HOLDING AG Stock Roche Holding AG
-7.93% 200B
AMGEN INC. Stock Amgen Inc.
+7.68% 166B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 300485 Stock
  4. Financials Beijing Science Sun Pharmaceutical Co., Ltd.